Oxaliplatin
EDQM grants CEP to Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine Co.,Ltd., leading chinese producer of API, is the first non-European pharmaceutical company being granted a CEP for Oxaliplatin.
Dolder Pharma is proud of being the technical support and regulatory affairs partner in the successful registration of this anti-neoplastic. As a result, finished product manufacturers finally gain access to a competitively priced alternative to established providers.
Among other indications, Oxaliplatin is used in the treatment of colorectal cancer.
Technical documents are available upon request.
Your contact
Dr. Giovanni La Rosa
Sales Manager Pharma
Tel: +41 (0)61 326 62 33
Fax: +41 (0)61 326 62 04
eMail
Add this page to your favorites: www.dolder.com/oxaliplatin
Dolder Fine Chemicals: A reliable Partner - since 1898
Dolder Fine Chemicals is a highly qualified, special distributor with additional services for active pharmaceutical ingredients (API). We operate world-wide and set our focus on selected markets in Europe, Asia and Latin America.
